These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 22791998)

  • 1. Clinical utility of clocortolone pivalate for the treatment of corticosteroid-responsive skin disorders: a systematic review.
    Singh S; Mann BK
    Clin Cosmet Investig Dermatol; 2012; 5():61-8. PubMed ID: 22791998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Comprehensive Review of Clocortolone Pivalate 0.1% Cream: Structural Development, Formulation Characteristics, and Studies Supporting Treatment of Corticosteroid-responsive Dermatoses.
    Del Rosso JQ; Kircik L
    J Clin Aesthet Dermatol; 2012 Jul; 5(7):20-4. PubMed ID: 22798972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The treatment of inflammatory facial dermatoses with topical corticosteroids: focus on clocortolone pivalate 0.1% cream.
    Kircik LH; Del Rosso JQ
    J Drugs Dermatol; 2012 Oct; 11(10):1194-8. PubMed ID: 23134984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clocortolone pivalate: a topical corticosteroid with a unique structure.
    Kircik LH
    J Drugs Dermatol; 2013 Feb; 12(2):s3-4. PubMed ID: 23377404
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A study to assess the occlusivity and moisturization potential of three topical corticosteroid products using the skin trauma after razor shaving (STARS) bioassay.
    Kircik LH
    J Drugs Dermatol; 2014 May; 13(5):582-5. PubMed ID: 24809882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adherence to clocortolone pivalate cream 0.1% in a pediatric population with atopic dermatitis.
    Conde JF; Kaur M; Fleischer AB; Tusa MG; Camacho F; Feldman SR
    Cutis; 2008 May; 81(5):435-41. PubMed ID: 18543596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transitioning from brand to generic with topical products and the importance of maintaining the formulation and therapeutic profiles of the original product: focus on clocortolone pivalate 0.1% cream.
    Del Rosso JQ; Kircik LH
    J Drugs Dermatol; 2014 Jul; 13(7):s77-83. PubMed ID: 25007376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of a midpotency topical corticosteroid and the clinical relevance of formulation characteristics in the management of commonly encountered eczematous and inflammatory dermatoses in adults and children: focus on the pharmacologic properties of clocortolone pivalate 0.1% cream.
    Del Rosso JQ; Kircik LH
    J Drugs Dermatol; 2013 Feb; 12(2):s5-s10. PubMed ID: 23377405
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clocortolone pivalate cream 0.1% used concomitantly with tacrolimus ointment 0.1% in atopic dermatitis.
    Torok HM; Maas-Irslinger R; Slayton RM
    Cutis; 2003 Aug; 72(2):161-6. PubMed ID: 12953943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clocortolone pivalate: a paired comparison clinical trial of a new topical steroid in eczema/atopic dermatitis.
    Rosenthal AL
    Cutis; 1980 Jan; 25(1):96-8. PubMed ID: 6986236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of clocortolone pivalate 0.1 percent cream in the treatment of atopic dermatitis, contact dermatitis, and seborrheic dermatitis.
    Nierman MM
    Cutis; 1981 Jun; 27(6):670-1. PubMed ID: 6453703
    [No Abstract]   [Full Text] [Related]  

  • 12. Topical tacrolimus for atopic dermatitis.
    Cury Martins J; Martins C; Aoki V; Gois AF; Ishii HA; da Silva EM
    Cochrane Database Syst Rev; 2015 Jul; 2015(7):CD009864. PubMed ID: 26132597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification and characterization of three impurities in clocortolone pivalate.
    Xu W; Jia X; Liu W; Zhang X; Chen Y; Zhou L; You S
    J Pharm Biomed Anal; 2012 Mar; 62():167-71. PubMed ID: 22264563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A systematic review of tacrolimus ointment compared with corticosteroids in the treatment of atopic dermatitis.
    Svensson A; Chambers C; Gånemo A; Mitchell SA
    Curr Med Res Opin; 2011 Jul; 27(7):1395-406. PubMed ID: 21563877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glucocorticoid corticosteroids for Duchenne muscular dystrophy.
    Manzur AY; Kuntzer T; Pike M; Swan A
    Cochrane Database Syst Rev; 2008 Jan; (1):CD003725. PubMed ID: 18254031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapy of atopic eczema.
    Werfel T; Claes C; Kulp W; Greiner W; von der Schulenburg JM
    GMS Health Technol Assess; 2006 Oct; 2():Doc19. PubMed ID: 21289970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucocorticoid corticosteroids for Duchenne muscular dystrophy.
    Manzur AY; Kuntzer T; Pike M; Swan A
    Cochrane Database Syst Rev; 2004; (2):CD003725. PubMed ID: 15106215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Topical cyclosporine for atopic keratoconjunctivitis.
    González-López JJ; López-Alcalde J; Morcillo Laiz R; Fernández Buenaga R; Rebolleda Fernández G
    Cochrane Database Syst Rev; 2012 Sep; (9):CD009078. PubMed ID: 22972132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Understanding the correlation between structure and dynamics of clocortolone pivalate by solid state NMR measurement.
    Dey KK; Gayen S; Ghosh M
    RSC Adv; 2020 Jan; 10(8):4310-4321. PubMed ID: 35495240
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.